Abstract

Background: Expression of transforming growth factor–β1 (TGF-β1) is central to vascular repair due to its effects on smooth muscle cell, monocyte/macrophage, leucocyte, and extracellular matrix accumulation and proliferation. Genetic polymorphism at position +915 of the TGF-β1 gene determines the degree of cytokine production in response to injury. We investigated this allelic variation on the development of cardiac transplant–related coronary vasculopathy (CV). MethodsUsing sequence-specific primers to the TGF-β1 gene region of interest, a polymerase chain reaction (PCR) and gel electrophoresis identified the genotype in 129 cardiac transplant recipients. An association was sought between the presence of a high- (GG) or low/intermediate-producing (CC/GC) genotype and the development of coronary vasculopathy diagnosed by coronary angiography. ResultsC allele carriers made up 10.9% of the recipient population but were significantly less likely to develop coronary vasculopathy (p = 0.0361). Mean time to diagnosis was 1240.5 days in G homozygotes relative to 2266.5 days in C allele carriers (p = 0.002). Pre- and 1-year posttransplant clinical variables were equivalent between the 2 groups. Multivariate analysis identified the GG genotype (p = 0.042, hazard ratio 3.01, [95% CI, 1.056–10.99]), donor age (p = 0.002, hazard ratio 1.063, [95% CI, 1.029–1.097]), and number of acute-rejection episodes of grade 3 or greater in the first year (p = 0.029, hazard ratio 1.11, [95% CI, 1.05–1.26]) as significant predictors of vasculopathy. ConclusionsThis study demonstrates a correlation between a high-producing TGF-β1 genotype and an earlier onset of cardiac-transplant coronary vasculopathy. This gives an important insight into the pathophysiology of cardiac transplant vasculopathy and suggests new treatment options.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call